NASDAQ:AMRX Amneal Pharmaceuticals (AMRX) Stock Price, News & Analysis $20.38 -0.10 (-0.49%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$20.41 +0.03 (+0.17%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Amneal Pharmaceuticals Stock (NASDAQ:AMRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Amneal Pharmaceuticals alerts:Sign Up Key Stats Today's Range$19.93▼$20.4950-Day Range$16.65▼$20.5052-Week Range$9.99▼$21.17Volume4.93 million shsAverage Volume3.86 million shsMarket Capitalization$6.51 billionP/E Ratio41.59Dividend YieldN/APrice Target$21.25Consensus RatingModerate Buy Company Overview Amneal Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging. The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments. Amneal’s specialty pharmaceutical portfolio includes branded therapies such as RYTARY, an extended-release treatment for Parkinson’s disease, and other products focused on neurology and related conditions. Amneal was formed in 2017 through the combination of privately held Amneal Pharmaceuticals and Impax Laboratories. The company is headquartered in Bridgewater, New Jersey, and serves customers in the United States and international markets through its commercial, manufacturing and distribution operations. Its leadership includes co-chief executive officers Chirag Patel and Chintu Patel, who are co-founders of Amneal Pharmaceuticals.AI Generated. May Contain Errors. Read More Amneal Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreAMRX MarketRank™: 3.780029526235 of 5 starsAmneal Pharmaceuticals scored higher than 76% of companies evaluated by MarketBeat, and ranked 140th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.7 / 5Analyst RatingModerate Buy Consensus RatingAmneal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 9 buy ratings, no hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Amneal Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAmneal Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amneal Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth13.68% Earnings GrowthEarnings for Amneal Pharmaceuticals are expected to grow by 13.68% in the coming year, from $0.95 to $1.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amneal Pharmaceuticals is 41.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.38.Price to Earnings Ratio vs. SectorThe P/E ratio of Amneal Pharmaceuticals is 41.59, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.33.Price to Earnings Growth RatioAmneal Pharmaceuticals has a PEG Ratio of 2.39. PEG Ratios above 1 indicate that a company could be overvalued. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.27% of the float of Amneal Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmneal Pharmaceuticals has a short interest ratio ("days to cover") of 3.06, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amneal Pharmaceuticals has recently decreased by 0.10%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmneal Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmneal Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.04 News SentimentAmneal Pharmaceuticals has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Amneal Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 4 people have searched for AMRX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Amneal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amneal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,216,567.00 in company stock.Percentage Held by Insiders17.30% of the stock of Amneal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions31.82% of the stock of Amneal Pharmaceuticals is held by institutions.Read more about Amneal Pharmaceuticals' insider trading history. Receive AMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMRX Stock News HeadlinesAmneal Pharmaceuticals (AMRX) Faces A Valuation Test Following Slowing Growth ConcernsOctober 24 at 5:12 PM | finance.yahoo.comAmneal Pharmaceuticals (NASDAQ:AMRX) Stock Gets Price Target Boost from JPMorgan Chase & Co.October 24 at 2:26 AM | americanbankingnews.comWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the big tech names pouring billions into data centers. Walmart's $24 million satellite network, AMR's Sabre system, and Capital One's 36,114 pricing tests all prove the same thing: compute has always been business's biggest moat, and it's about to get cheaper than ever. Porter Stansberry says one overlooked, government-protected sector is positioned to absorb this near-free compute boom and could become the next Magnificent 7.October 25 at 1:00 AM | Porter & Company (Ad)Amneal to Report Third Quarter 2026 Results on November 3, 2026October 8, 2026 | globenewswire.comAmneal Pharmaceuticals (AMRX) Stock Gets Fair Value Bump After Analyst Backing For New LaunchesOctober 3, 2026 | finance.yahoo.comOppenheimer initiates coverage of Amneal Pharmaceuticals at outperformSeptember 24, 2026 | msn.comAmneal Pharmaceuticals' Biosimilars, Specialty Growth Reshape Earnings Profile, Oppenheimer SaysSeptember 23, 2026 | finance.yahoo.comAmneal: Even My Bull Case Barely Justifies $20/ShareSeptember 22, 2026 | seekingalpha.comSee More Headlines AMRX Stock Analysis - Frequently Asked Questions How have AMRX shares performed this year? Amneal Pharmaceuticals' stock was trading at $12.60 at the start of the year. Since then, AMRX shares have increased by 61.7% and is now trading at $20.38. How were Amneal Pharmaceuticals' earnings last quarter? Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced its quarterly earnings results on Thursday, July, 30th. The company reported $0.30 earnings per share for the quarter, topping analysts' consensus estimates of $0.24 by $0.06. The firm had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative trailing twelve-month return on equity of 584.46%. Read the conference call transcript. Who are Amneal Pharmaceuticals' major shareholders? Top institutional investors of Amneal Pharmaceuticals include Assenagon Asset Management S.A. (0.63%), Congress Asset Management Co. (0.48%), Signature Wealth Management Partners LLC (0.07%) and Diversify Advisory Services LLC (0.04%). Insiders that own company stock include Tushar Bhikhubhai Patel, Gautam Patel, Ted C Nark, Nikita Shah, John Kiely, Andrew S Boyer, Deborah M Autor and Jason B Daly. View institutional ownership trends. How do I buy shares of Amneal Pharmaceuticals? Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amneal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amneal Pharmaceuticals investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Tesla (TSLA), NIO (NIO), Palantir Technologies (PLTR) and Pfizer (PFE). Company Calendar Last Earnings7/30/2026Today10/25/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 AMRX's financial health is in the Green zone, according to TradeSmith. AMRX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AMRX Previous SymbolNASDAQ:AMRX CIK1723128 Webamneal.com Phone908-947-3120Fax908-947-3146Employees8,500Year Founded2002Price Target and Rating Average Price Target for Amneal Pharmaceuticals$21.25 High Price Target$27.00 Low Price Target$13.00 Potential Upside/Downside+4.3%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)$0.49 Trailing P/E Ratio41.59 Forward P/E Ratio21.45 P/E Growth2.39Net Income$72.06 million Net Margins5.05% Pretax Margin6.45% Return on Equity-584.46% Return on Assets7.78% Debt Debt-to-Equity Ratio77.65 Current Ratio2.20 Quick Ratio1.44 Sales & Book Value Annual Sales$3.02 billion Price / Sales2.16 Cash Flow$1.56 per share Price / Cash Flow13.05 Book Value($0.23) per share Price / Book-88.61Miscellaneous Outstanding Shares319,350,000Free Float264,106,000Market Cap$6.51 billion OptionableOptionable Beta1.22 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:AMRX) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
